Serum concentrations of delta 5-3 beta-hydroxysteroids in type 2 diabetes mellitus.
We examined the serum concentrations of delta(5)-3beta-hydroxysteroids, pregnenolone (Preg), 17-hydroxypregnenolone (17-OH-Preg), dehydroepiandrosterone (DHEA), androstenediol (ADIOL) and their sulfates in 30 well controlled (Group I: HbA1c<7.0%) and 15 poorly controlled (Group II: HbA1c>7.1%) type 2 diabetic patients, and 30 normal controls. These patients were treated with diet therapy or anti-diabetic agent. The distribution of gender and age of the subjects were matched between the groups. The serum levels of sulfo-conjugated and unconjugated steroids described above were measured by GC-MS and enzyme immunoassay (EIA), respectively. The serum levels of the entire sulfo-conjugated steroid measured in this study were significantly lower in Groups I and II than in controls. On the other hand, Preg levels in both Groups I and II were significantly higher than those in controls, whereas the serum levels of the downstream unconjugated steroids were not different from controls. To investigate the effect of sulfonylurea (SU) on the serum levels of steroids, the serum concentrations of steroids between the patients who were treated with diet therapy and SU agent were compared in Group I. No significant differences were observed between both groups. These results suggest that (1) since increased Preg levels did not cause any changes in the downstream delta(5)-3beta-hydroxysteroid levels, the metabolic pathway of delta(4)-3-ketosteroids may be accelerated in type 2 diabetes; (2) serum steroid levels were not affected by SU treatment; (3) sulfo-conjugated steroid catabolism was altered in type 2 diabetes; (4) the decreased sulfo-conjugated steroids especially ADIOLS may contribute to the alteration of sex steroid levels and onset or exacerbate infectious diseases in diabetes.
Tagawa
Noriko
N
Clinical Chemistry Laboratory, Kobe Pharmaceutical University, Japan.
Ohta
Mitsuhiro
M
Nakamura
Naoto
N
Nakano
Koji
K
Obayashi
Hiroshi
H
Kobayashi
Yoshiharu
Y
D006907:17-alpha-Hydroxypregnenolone / Q000097:blood* / Q000627:therapeutic use; D000328:Adult; D015114:Androstenediol / Q000097:blood* / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000097:blood* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011284:Pregnenolone / Q000097:blood* / Q000627:therapeutic use; D018709:Statistics, Nonparametric
D006907:17-alpha-Hydroxypregnenolone; D003687:Dehydroepiandrosterone; D011284:Pregnenolone; D015114:Androstenediol